ATI Pharmacology Proctored Test
i i i
Bank i
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
, Stuvia.com - The Marketplace to Buy and Sell your Study Material
ATI Pharmacology Proctored Test Bank
i i i i
ATI Pharmacology Proctored Exam, Test Bank(100 % Of 313 Verified Questions an
i i i i i i i i i i i
ALL CORRECT Answers), GRADED A+
i i i i i
1. i1) iA inurse iis icaring ifor ia iclient iwith 3. Calcitonin i(Miacalcin)
i hyperparathyroidism iand inotes ithat ithe iRationale:
iclient's iserum icalcium i level i is i13 img/dL. The inormal iserum icalcium ilevel iis i8.6 ito i10.0 img/dL. iThis iclient iis iexperiencing
iWhich i medication i should i the i nurse i prepare ihypercalcemia. iCalcium igluconateiandcalciumchloridearemedications iusedforthe
ito iadminister ias iprescribed ito ithe iclient? itreatment iof itetany, iwhich ioccurs ias ia iresult iof iacute ihypocalcemia. iIn
1. Calcium i chloride ihypercalcemia, ilargeidoses iofivitamin iD ineeditoibeiavoided. iCalcitonin, ia ithyroid
2. Calcium igluconate ihormone, idecreases ithe iplasma icalcium ilevel iby iinhibiting ibone iresorption iand
3. Calcitonin i(Miacalcin) ilowering ithe iserum icalciumiconcentration.
4. Large idoses iof ivitamin i D
2. i 2.) i Oral i iron i supplements i are i prescribed 4. Orange i juice
iforia i 6-year-old i child iwith i iron ideficiency iRationale:
ianemia. i The i nurse i instructs i the i mother i to Vitamin iC iincreases ithe iabsorption iof iiron iby ithe ibody. iThe imother ishould ibe
iadminister i the i iron i with i which i best i food iinstructeditoiadministeritheimedicationiwith ia icitrusifruitior ia ijuiceithatiis ihighiin ivitamin
iitem? iC.iMilkmayiaffectabsorptioniofitheiiron.iWateriwillinotiassistiiniabsorption.iOrangeijuice
1. Milk icontains ia igreater iamount iof ivitamin iC ithan iapple ijuice.
2. Water
3. Apple i juice
4. Orange ijuice
3. i3.) iSalicylic iacid iis iprescribed ifor ia 1. iTinnitus
iclientiwith i a i diagnosis i of i psoriasis. iThe iRationale:
inurse imonitors ithe iclient, iknowing ithat Salicylic iacid iis iabsorbed ireadily ithrough ithe iskin, iand isystemic itoxicity i(salicylism)ican
iwhich iof ithe ifollowing iwould iindicate ithe iresult.iSymptoms iincludeitinnitus,idizziness,ihyperpnea,iandipsychological
ipresenceiof i systemic i toxicity i from i this idisturbances. iConstipation iand idiarrhea iareinot iassociated iwith isalicylism.
i medication?
1. Tinnitus
2. Diarrhea
3. Constipation
4. Decreased i respirations 4. iAt ileast i30 iminutes ibeforeexposure ito ithe isun
4. i 4.) iThe icamp inurse iasks ithe ichildren iRationale:
i preparing ito iswim iin ithe ilake iif ithey ihave Sunscreensiareimostieffectiveiwheniappliediat ileast i30 iminutes ibeforeexposureitoithe
applied isunscreen. iThe inurse ireminds ithe
i isun iso ithat ithey ican ipenetrate ithe iskin. iAll isunscreens ishould ibe ireapplied iafter
ichildren i that i chemical i sunscreens i are i most iswimming ior isweating.
ieffective iwhen i applied:
1. Immediately ibefore iswimming
2. 15 iminutes ibefore iexposure ito ithe isun
3. Immediately i before i exposure ito i the i sun
4. At ileast i 30 i minutes i before i exposure
i toithe i sun
3. iInforming itheiclientithatithis iis inormaliRationale:
5. i5.) iMafenide iacetate i(Sulfamylon) iis Mafenideacetateis ibacteriostatic iforgram-negativeandgram-positive iorganisms
i prescribed ifor ithe iclient iwith ia iburn iinjury. iandiisiuseditoitreatburns itoireducebacteriaipresentiiniavascularitissues. iTheiclient
When i applying i the i medication, i the i client
i ishouldibeiinformedithatitheimedicationiwillicauseilocalidiscomfortiandiburningiand
icomplains i of i local i discomfort i and i burning. ithat ithis iis ia inormal ireaction; ithereforeioptions i1, i2, iand i4 iareiincorrect
iWhich iof ithe ifollowing iis ithe imost
iappropriate inursing iaction?
1. Notifying i the i registered i nurse
2. Discontinuing i the i medication
3. Informing ithe i client ithat ithis i is inormal
4. Applying i a i thinner i film i than
i prescribedito ithe iburn i site
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
, Stuvia.com - The Marketplace to Buy and Sell your Study Material
1. Hyperventilation
6. i 6.) i The i burn iclient i is i receiving i treatments i of
Rationale:
i
i topical imafenide iacetate(Sulfamylon) itothe
Mafenideacetateiisiaicarbonicianhydraseinhibitoriandicanisuppressirenalexcretioniof
isite iof iinjury. iThe inurse imonitors ithe iclient,
iacid, ithereby icausing iacidosis. iClients ireceiving ithis itreatment ishould ibe
iknowing ithat i which iof i the ifollowing iindicates
imonitored ifor isigns iof ian iacid-base iimbalance i(hyperventilation). iIf ithis ioccurs, ithe
ithat i a i systemic i effect i has ioccurred?
imedication ishouldibeidiscontinuedifor i1 itoi2 idays. iOptions i3 iand i4 idescribeilocal
i1.Hyperventilation
iratherithanisystemicieffects.iAnielevatedibloodipressureimayibeiexpectedifromitheipain
2.Elevated iblood i pressure
ithat ioccurs iwith ia iburn iinjury.
i3.Local ipain iat ithe iburn
isitei4.Local irash iat ithe iburn
isite 2. Triglyceride ilevel
Rationale:
i
7. i7.) iIsotretinoin iis iprescribed ifor ia iclient iwith
Isotretinoinican ielevateitriglycerideilevels. iBlooditriglycerideilevels ishouldibe
isevere iacne. iBefore ithe iadministration iof ithis
imeasured ibefore itreatment iand iperiodically ithereafter iuntil ithe ieffect ion ithe
medication, ithe inurse ianticipates ithat iwhich
i
itriglycerides ihas ibeenievaluated.iOptions i1,i3, iandi4 idoinotineeditoibeimonitored
ilaboratory itest iwill ibe iprescribed?
ispecifically iduring ithis itreatment.
1. Platelet i count
2. Triglyceride i level
3. Complete i blood i icount
4. White i blood i cell i count 1. Vitamin iA
iRationale:
8. i8.) iA iclient iwith isevere iacne iis iseen iin ithe
Isotretinoinis iametabolite iof ivitamin iAand icanproducegeneralizedintensification
i clinic iand ithe ihealth icare iprovider i(HCP)
iof iisotretinoin itoxicity. iBecause iof ithe ipotential ifor iincreased itoxicity, ivitamin iA
i prescribes iisotretinoin. iThe inurse ireviews ithe
isupplementsshould ibe idiscontinued ibeforeisotretinointherapy.Options i2, i3, iand i4
iclient's imedication irecord iand iwould icontact
iare inot icontraindicated iwith ithe iuse iof iisotretinoin.
ithe i(HCP) iif ithe iclient i is itaking iwhich
imedication?
1. Vitamin iA
2. Digoxin i(Lanoxin)
3. Furosemide i(Lasix)
4. Phenytoin i (Dilantin) 2. Axilla
iRationale
9. i9.) iThe inurse i is i applying i a i topical
:
icorticosteroid ito i a iclient iwith ieczema. i The
Topicalcorticosteroidsc i anibeiabsorbedintoitheisystemicicirculation.iAbsorptioniis
inurse iwould imonitor ifor ithe ipotential ifor
ihigher ifrom iregions iwhere ithe iskin iis iespecially ipermeable i(scalp, iaxilla, iface,
iincreased isystemic iabsorption i of ithe
ieyelids, ineck, iperineum, igenitalia), iand ilower ifrom iregions iin iwhich ipermeability iis
imedication i if i the i medication i were i being
ipoor i(back, ipalms, isoles).
iapplied ito iwhich iof ithe ifollowing ibody iareas?
1. Back
2. Axilla
3. Soles i of i the i feet
4. Palms iof i the i hands
1. Acne
10. i10.) iThe iclinic inurse iis iperforming ian
iRationale
iadmission iassessment ion ia iclient. iThe inurse
:
inotes ithat ithe iclient iis itaking iazelaic iacid
Azelaiciacidiis ia itopical imedicationiuseditoitreatimild itoimoderateiacne. iTheiacid
i(Azelex). iBecause iof ithe imedication
iappears ito iwork iby isuppressing ithe igrowth iof iPropionibacterium iacnes iand
iprescription, ithe inurse iwould isuspect ithat ithe
idecreasingitheiproliferationiofikeratinocytes. iOptions i2, i3, iand i4 iareiincorrect.
iclient iis ibeing itreated ifor:
1. Acne
2. Eczema
3. Hair iloss
4. Herpes isimplex
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
, Stuvia.com - The Marketplace to Buy and Sell your Study Material
3. i"Theimedicationiwillipermanentlyistain imy iskin."iRationale:
11. i 11.) i The i health i care i provider i has i prescribed i silver
isulfadiazine i (Silvadene) i for i the i client i with i a Silver isulfadiazine i(Silvadene) iis ian iantibacterial ithat ihas ia ibroad ispectrumiof
iactivityiagainstigram-negativebacteria,igram-positiveibacteria,iand iyeast.
i partial- ithickness iburn, iwhich ihas icultured ipositive
iIt iis iapplied idirectly itoitheiwound itoiassist iin ihealing. iItidoes inot istain ithe
ifor igram- inegative ibacteria. iThe inurse iis
iskin.
ireinforcing iinformation ito i the i client i about ithe
i medication. i Whichistatement i made iby i the i client
i indicates i a ilack i of iunderstanding i about ithe
i treatments?
1. "The imedication iis ian iantibacterial."
2. "The i medication i will i help i heal i the i burn."
3. "The i medication i will i permanently i stain i my i skin."
4. "The imedication i should ibe iapplied idirectly i to 1. iNotifyitheiregisteredinurse.
i theiwound." iRationale:
When iantineoplastic imedications i(Chemotheraputic iAgents) iare
12. i12.) iA inurse i is icaring ifor ia iclient iwho iis ireceiving
iadministeredviaiIV,igreatcaremustibeitakenitoipreventtheimedicationifrom
i an iintravenous i(IV) iinfusion iof ian iantineoplastic
iescaping iinto ithe itissues isurrounding ithe iinjection isite, ibecause ipain, itissue
i medication. iDuring itheinfusion, ithe iclient icomplains
idamage, iand inecrosis ican iresult. iThe inurse imonitors ifor isigns iof
iof i pain i at i the i insertion i site. i During i an i inspection
iextravasation, isuch ias iredness ior iswelling iat ithe iinsertion isite iand ia
i of ithe isite, ithe inurse inotes iredness iand iswelling
idecreasedinfusionirate.iIfiextravasationoccurs,itheiregisterednurseneeds
iand ithat ithe irate iof iinfusion iof ithe imedication
ito ibe inotified; ihe ior ishe iwill ithen icontact ithe ihealth icare iprovider.
ihas islowed. iThe inurse ishould itake iwhich
iappropriate iaction?
1. Notify i the i registered i nurse.
2. Administer ipainmedicationtoreduce i the
idiscomfort.
3. Apply i ice i and i maintain ithe i infusion i rate,
i asiprescribed.
4. Elevate i the i extremity i of i the i IV i site, i and i slow 4. iPulmonary ifunction istudies
i theiinfusion. iRationale:
Bleomyciniisianantineoplasticmedicationi(ChemotheraputiciAgents)ithat
13. i 13.) i The iclient iwith i squamous icell i carcinoma i of
ican icause iinterstitial ipneumonitis, iwhich ican iprogress ito ipulmonary ifibrosis.
itheilarynx iis ireceiving ibleomycin iintravenously. iThe
iPulmonaryifunctionistudiesialongiwithihematological,ihepatic, iandirenal
inurse icaring ifor ithe iclient ianticipates ithat iwhich
ifunction itests ineed ito ibe imonitored. iThe inurse ineeds ito imonitor ilung
idiagnostic istudy iwill ibe iprescribed?
isounds iforidyspnea iandicrackles,iwhichiindicateipulmonaryitoxicity.iThe
1. Echocardiography
imedication ineeds ito ibe idiscontinued iimmediately iif ipulmonary itoxicity
2. Electrocardiography
ioccurs. iOptions i1, i2, iand i3 iare iunrelated ito ithe ispecific iuse iof ithis
3. Cervical i radiography
imedication.
4. Pulmonary i function i studies
2. Uric iacidlevel
iRationale:
Busulfan i(Myleran) ican icause ian iincrease iin ithe iuric iacid ilevel.
14. i 14.) i The iclient i with i acute imyelocytic ileukemia i is
iHyperuricemiacanproduceuricacidnephropathy,irenalstones, iandacute
being itreated iwith ibusulfan i(Myleran). iWhich
i
irenal ifailure. iOptions i1, i3, iand i4 iare inot ispecifically irelated ito ithis
ilaboratory i value iwould i the inurse ispecifically
imedication.
imonitor iduring itreatment iwith ithis imedication?
1. Clotting itime
2. Uric iacid i level
3. Potassium ilevel
4. Blood i glucose i level
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
i i i
Bank i
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
, Stuvia.com - The Marketplace to Buy and Sell your Study Material
ATI Pharmacology Proctored Test Bank
i i i i
ATI Pharmacology Proctored Exam, Test Bank(100 % Of 313 Verified Questions an
i i i i i i i i i i i
ALL CORRECT Answers), GRADED A+
i i i i i
1. i1) iA inurse iis icaring ifor ia iclient iwith 3. Calcitonin i(Miacalcin)
i hyperparathyroidism iand inotes ithat ithe iRationale:
iclient's iserum icalcium i level i is i13 img/dL. The inormal iserum icalcium ilevel iis i8.6 ito i10.0 img/dL. iThis iclient iis iexperiencing
iWhich i medication i should i the i nurse i prepare ihypercalcemia. iCalcium igluconateiandcalciumchloridearemedications iusedforthe
ito iadminister ias iprescribed ito ithe iclient? itreatment iof itetany, iwhich ioccurs ias ia iresult iof iacute ihypocalcemia. iIn
1. Calcium i chloride ihypercalcemia, ilargeidoses iofivitamin iD ineeditoibeiavoided. iCalcitonin, ia ithyroid
2. Calcium igluconate ihormone, idecreases ithe iplasma icalcium ilevel iby iinhibiting ibone iresorption iand
3. Calcitonin i(Miacalcin) ilowering ithe iserum icalciumiconcentration.
4. Large idoses iof ivitamin i D
2. i 2.) i Oral i iron i supplements i are i prescribed 4. Orange i juice
iforia i 6-year-old i child iwith i iron ideficiency iRationale:
ianemia. i The i nurse i instructs i the i mother i to Vitamin iC iincreases ithe iabsorption iof iiron iby ithe ibody. iThe imother ishould ibe
iadminister i the i iron i with i which i best i food iinstructeditoiadministeritheimedicationiwith ia icitrusifruitior ia ijuiceithatiis ihighiin ivitamin
iitem? iC.iMilkmayiaffectabsorptioniofitheiiron.iWateriwillinotiassistiiniabsorption.iOrangeijuice
1. Milk icontains ia igreater iamount iof ivitamin iC ithan iapple ijuice.
2. Water
3. Apple i juice
4. Orange ijuice
3. i3.) iSalicylic iacid iis iprescribed ifor ia 1. iTinnitus
iclientiwith i a i diagnosis i of i psoriasis. iThe iRationale:
inurse imonitors ithe iclient, iknowing ithat Salicylic iacid iis iabsorbed ireadily ithrough ithe iskin, iand isystemic itoxicity i(salicylism)ican
iwhich iof ithe ifollowing iwould iindicate ithe iresult.iSymptoms iincludeitinnitus,idizziness,ihyperpnea,iandipsychological
ipresenceiof i systemic i toxicity i from i this idisturbances. iConstipation iand idiarrhea iareinot iassociated iwith isalicylism.
i medication?
1. Tinnitus
2. Diarrhea
3. Constipation
4. Decreased i respirations 4. iAt ileast i30 iminutes ibeforeexposure ito ithe isun
4. i 4.) iThe icamp inurse iasks ithe ichildren iRationale:
i preparing ito iswim iin ithe ilake iif ithey ihave Sunscreensiareimostieffectiveiwheniappliediat ileast i30 iminutes ibeforeexposureitoithe
applied isunscreen. iThe inurse ireminds ithe
i isun iso ithat ithey ican ipenetrate ithe iskin. iAll isunscreens ishould ibe ireapplied iafter
ichildren i that i chemical i sunscreens i are i most iswimming ior isweating.
ieffective iwhen i applied:
1. Immediately ibefore iswimming
2. 15 iminutes ibefore iexposure ito ithe isun
3. Immediately i before i exposure ito i the i sun
4. At ileast i 30 i minutes i before i exposure
i toithe i sun
3. iInforming itheiclientithatithis iis inormaliRationale:
5. i5.) iMafenide iacetate i(Sulfamylon) iis Mafenideacetateis ibacteriostatic iforgram-negativeandgram-positive iorganisms
i prescribed ifor ithe iclient iwith ia iburn iinjury. iandiisiuseditoitreatburns itoireducebacteriaipresentiiniavascularitissues. iTheiclient
When i applying i the i medication, i the i client
i ishouldibeiinformedithatitheimedicationiwillicauseilocalidiscomfortiandiburningiand
icomplains i of i local i discomfort i and i burning. ithat ithis iis ia inormal ireaction; ithereforeioptions i1, i2, iand i4 iareiincorrect
iWhich iof ithe ifollowing iis ithe imost
iappropriate inursing iaction?
1. Notifying i the i registered i nurse
2. Discontinuing i the i medication
3. Informing ithe i client ithat ithis i is inormal
4. Applying i a i thinner i film i than
i prescribedito ithe iburn i site
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
, Stuvia.com - The Marketplace to Buy and Sell your Study Material
1. Hyperventilation
6. i 6.) i The i burn iclient i is i receiving i treatments i of
Rationale:
i
i topical imafenide iacetate(Sulfamylon) itothe
Mafenideacetateiisiaicarbonicianhydraseinhibitoriandicanisuppressirenalexcretioniof
isite iof iinjury. iThe inurse imonitors ithe iclient,
iacid, ithereby icausing iacidosis. iClients ireceiving ithis itreatment ishould ibe
iknowing ithat i which iof i the ifollowing iindicates
imonitored ifor isigns iof ian iacid-base iimbalance i(hyperventilation). iIf ithis ioccurs, ithe
ithat i a i systemic i effect i has ioccurred?
imedication ishouldibeidiscontinuedifor i1 itoi2 idays. iOptions i3 iand i4 idescribeilocal
i1.Hyperventilation
iratherithanisystemicieffects.iAnielevatedibloodipressureimayibeiexpectedifromitheipain
2.Elevated iblood i pressure
ithat ioccurs iwith ia iburn iinjury.
i3.Local ipain iat ithe iburn
isitei4.Local irash iat ithe iburn
isite 2. Triglyceride ilevel
Rationale:
i
7. i7.) iIsotretinoin iis iprescribed ifor ia iclient iwith
Isotretinoinican ielevateitriglycerideilevels. iBlooditriglycerideilevels ishouldibe
isevere iacne. iBefore ithe iadministration iof ithis
imeasured ibefore itreatment iand iperiodically ithereafter iuntil ithe ieffect ion ithe
medication, ithe inurse ianticipates ithat iwhich
i
itriglycerides ihas ibeenievaluated.iOptions i1,i3, iandi4 idoinotineeditoibeimonitored
ilaboratory itest iwill ibe iprescribed?
ispecifically iduring ithis itreatment.
1. Platelet i count
2. Triglyceride i level
3. Complete i blood i icount
4. White i blood i cell i count 1. Vitamin iA
iRationale:
8. i8.) iA iclient iwith isevere iacne iis iseen iin ithe
Isotretinoinis iametabolite iof ivitamin iAand icanproducegeneralizedintensification
i clinic iand ithe ihealth icare iprovider i(HCP)
iof iisotretinoin itoxicity. iBecause iof ithe ipotential ifor iincreased itoxicity, ivitamin iA
i prescribes iisotretinoin. iThe inurse ireviews ithe
isupplementsshould ibe idiscontinued ibeforeisotretinointherapy.Options i2, i3, iand i4
iclient's imedication irecord iand iwould icontact
iare inot icontraindicated iwith ithe iuse iof iisotretinoin.
ithe i(HCP) iif ithe iclient i is itaking iwhich
imedication?
1. Vitamin iA
2. Digoxin i(Lanoxin)
3. Furosemide i(Lasix)
4. Phenytoin i (Dilantin) 2. Axilla
iRationale
9. i9.) iThe inurse i is i applying i a i topical
:
icorticosteroid ito i a iclient iwith ieczema. i The
Topicalcorticosteroidsc i anibeiabsorbedintoitheisystemicicirculation.iAbsorptioniis
inurse iwould imonitor ifor ithe ipotential ifor
ihigher ifrom iregions iwhere ithe iskin iis iespecially ipermeable i(scalp, iaxilla, iface,
iincreased isystemic iabsorption i of ithe
ieyelids, ineck, iperineum, igenitalia), iand ilower ifrom iregions iin iwhich ipermeability iis
imedication i if i the i medication i were i being
ipoor i(back, ipalms, isoles).
iapplied ito iwhich iof ithe ifollowing ibody iareas?
1. Back
2. Axilla
3. Soles i of i the i feet
4. Palms iof i the i hands
1. Acne
10. i10.) iThe iclinic inurse iis iperforming ian
iRationale
iadmission iassessment ion ia iclient. iThe inurse
:
inotes ithat ithe iclient iis itaking iazelaic iacid
Azelaiciacidiis ia itopical imedicationiuseditoitreatimild itoimoderateiacne. iTheiacid
i(Azelex). iBecause iof ithe imedication
iappears ito iwork iby isuppressing ithe igrowth iof iPropionibacterium iacnes iand
iprescription, ithe inurse iwould isuspect ithat ithe
idecreasingitheiproliferationiofikeratinocytes. iOptions i2, i3, iand i4 iareiincorrect.
iclient iis ibeing itreated ifor:
1. Acne
2. Eczema
3. Hair iloss
4. Herpes isimplex
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
, Stuvia.com - The Marketplace to Buy and Sell your Study Material
3. i"Theimedicationiwillipermanentlyistain imy iskin."iRationale:
11. i 11.) i The i health i care i provider i has i prescribed i silver
isulfadiazine i (Silvadene) i for i the i client i with i a Silver isulfadiazine i(Silvadene) iis ian iantibacterial ithat ihas ia ibroad ispectrumiof
iactivityiagainstigram-negativebacteria,igram-positiveibacteria,iand iyeast.
i partial- ithickness iburn, iwhich ihas icultured ipositive
iIt iis iapplied idirectly itoitheiwound itoiassist iin ihealing. iItidoes inot istain ithe
ifor igram- inegative ibacteria. iThe inurse iis
iskin.
ireinforcing iinformation ito i the i client i about ithe
i medication. i Whichistatement i made iby i the i client
i indicates i a ilack i of iunderstanding i about ithe
i treatments?
1. "The imedication iis ian iantibacterial."
2. "The i medication i will i help i heal i the i burn."
3. "The i medication i will i permanently i stain i my i skin."
4. "The imedication i should ibe iapplied idirectly i to 1. iNotifyitheiregisteredinurse.
i theiwound." iRationale:
When iantineoplastic imedications i(Chemotheraputic iAgents) iare
12. i12.) iA inurse i is icaring ifor ia iclient iwho iis ireceiving
iadministeredviaiIV,igreatcaremustibeitakenitoipreventtheimedicationifrom
i an iintravenous i(IV) iinfusion iof ian iantineoplastic
iescaping iinto ithe itissues isurrounding ithe iinjection isite, ibecause ipain, itissue
i medication. iDuring itheinfusion, ithe iclient icomplains
idamage, iand inecrosis ican iresult. iThe inurse imonitors ifor isigns iof
iof i pain i at i the i insertion i site. i During i an i inspection
iextravasation, isuch ias iredness ior iswelling iat ithe iinsertion isite iand ia
i of ithe isite, ithe inurse inotes iredness iand iswelling
idecreasedinfusionirate.iIfiextravasationoccurs,itheiregisterednurseneeds
iand ithat ithe irate iof iinfusion iof ithe imedication
ito ibe inotified; ihe ior ishe iwill ithen icontact ithe ihealth icare iprovider.
ihas islowed. iThe inurse ishould itake iwhich
iappropriate iaction?
1. Notify i the i registered i nurse.
2. Administer ipainmedicationtoreduce i the
idiscomfort.
3. Apply i ice i and i maintain ithe i infusion i rate,
i asiprescribed.
4. Elevate i the i extremity i of i the i IV i site, i and i slow 4. iPulmonary ifunction istudies
i theiinfusion. iRationale:
Bleomyciniisianantineoplasticmedicationi(ChemotheraputiciAgents)ithat
13. i 13.) i The iclient iwith i squamous icell i carcinoma i of
ican icause iinterstitial ipneumonitis, iwhich ican iprogress ito ipulmonary ifibrosis.
itheilarynx iis ireceiving ibleomycin iintravenously. iThe
iPulmonaryifunctionistudiesialongiwithihematological,ihepatic, iandirenal
inurse icaring ifor ithe iclient ianticipates ithat iwhich
ifunction itests ineed ito ibe imonitored. iThe inurse ineeds ito imonitor ilung
idiagnostic istudy iwill ibe iprescribed?
isounds iforidyspnea iandicrackles,iwhichiindicateipulmonaryitoxicity.iThe
1. Echocardiography
imedication ineeds ito ibe idiscontinued iimmediately iif ipulmonary itoxicity
2. Electrocardiography
ioccurs. iOptions i1, i2, iand i3 iare iunrelated ito ithe ispecific iuse iof ithis
3. Cervical i radiography
imedication.
4. Pulmonary i function i studies
2. Uric iacidlevel
iRationale:
Busulfan i(Myleran) ican icause ian iincrease iin ithe iuric iacid ilevel.
14. i 14.) i The iclient i with i acute imyelocytic ileukemia i is
iHyperuricemiacanproduceuricacidnephropathy,irenalstones, iandacute
being itreated iwith ibusulfan i(Myleran). iWhich
i
irenal ifailure. iOptions i1, i3, iand i4 iare inot ispecifically irelated ito ithis
ilaboratory i value iwould i the inurse ispecifically
imedication.
imonitor iduring itreatment iwith ithis imedication?
1. Clotting itime
2. Uric iacid i level
3. Potassium ilevel
4. Blood i glucose i level
Downloaded by: jasminenturner1993 |
Distribution of this document is illegal
